Understand the pricing, access and uptake potential of a potential gene therapy platform that the client wished to in-license
The pharma company had identified a autologous gene therapy platform being developed in multiple orphan indications as a target for in-licensing
Although all indications were rare, each had different landscapes and with different patient pathways. While the pivotal clinical trials were completed for 1 indication, they were still ongoing for the other planned indications